Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$3.21 - $12.40
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Last Price
Market Cap | $294.63M |
EV | $-34.80M |
Shares Outstanding | 82.15M |
Beta | 1.53 |
Analyst Rating | BUY |
Analyst Target Price | $16.13 |
P/E 2025E | - |
P/Revenue 2025E | 5.50x |
Revenue | - |
EPS | 30.80% |
Operating Cash Flow | - |
Free Cash Flow | - |
Revenue | -16.80% |
EPS | -21.30% |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | -240.87% |
ROE 2025E | -134.62% |
ROCE 2024 | -36.15% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Monte Rosa Therapeutics, Inc.
GLUE
Sector
Healthcare
Industry
Biotechnology
CEO
Warmuth, Markus
Employees
134
Website
www.monterosatx.comIPO Date
2021-06-24
Headquarters
321 Harrison Avenue, Suite 900, Boston, Massachusetts, 02118, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved